Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
Descripción del Articulo
Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this conditi...
Autores: | , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2020 |
Institución: | Colegio Médico del Perú |
Repositorio: | Acta Médica Peruana |
Lenguaje: | español |
OAI Identifier: | oai:amp.cmp.org.pe:article/1056 |
Enlace del recurso: | https://amp.cmp.org.pe/index.php/AMP/article/view/1056 |
Nivel de acceso: | acceso abierto |
Materia: | Microangiopatías trombóticas Tacrolimus Trasplante renal Thrombotic microangiopathies Kidney transplantation |
id |
REVCMP_2bc0640c69de5006de5cd924e50639a6 |
---|---|
oai_identifier_str |
oai:amp.cmp.org.pe:article/1056 |
network_acronym_str |
REVCMP |
network_name_str |
Acta Médica Peruana |
repository_id_str |
. |
spelling |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agentMicroangiopatía trombótica en el trasplante renal, el tacrolimus como causanteRodriguez-Mori, Juan E.Mego-Arellan, Denese C.Sumire-Umeres, JuliaAsato-Higa, CarmenRodríguez-Mori, Juan E.Mego-Arellan, Denese C.Sumire-Umeres, JuliaAsato-Higa, CarmenMicroangiopatías trombóticasTacrolimusTrasplante renalThrombotic microangiopathiesTacrolimusKidney transplantationThrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this condition presents in non-complete forms, which makes diagnosis difficult, and irreversible lesions may supervene. This case features the presence of a viral infection, and data suggesting rejection with the concomitant tacrolimus use. Therapy includes plasmapheresis and the use of monoclonal antibodies such as eculizumab. Nonetheless, in this particular case suspending therapy or switching from tacrolimus to another agent were good cost-effective measures.La microangiopatía trombótica (MAT) es una complicación poco frecuente asociada al uso de tacrolimus en el trasplante renal. Puede estar relacionado a infecciones, rechazo mediado por anticuerpos (RMA), recurrencia de enfermedad o MAT de novo y a toxicidad por inhibidores de la calcineurina. Por lo general, se presenta como formas incompletas, lo que hace difícil su diagnóstico, por lo que puede provocar lesiones irreversibles. El caso presentado comparte la presencia de infección viral, datos sugerentes de rechazo concomitantemente con el uso de tacrolimus. El tratamiento incluye plasmaferesis y anticuerpos monoclonales como eculizumab. Sin embargo, en el caso presentado la suspensión o cambio del tacrolimus fue una medida más costo-efectiva.Colegio Médico del Perú2020-12-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/105610.35663/amp.2020.374.1056ACTA MEDICA PERUANA; Vol. 37 No. 4 (2020): October - DecemberACTA MEDICA PERUANA; Vol. 37 Núm. 4 (2020): Octubre-Diciembre1728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1056/1243Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/10562024-07-26T07:32:27Z |
dc.title.none.fl_str_mv |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent Microangiopatía trombótica en el trasplante renal, el tacrolimus como causante |
title |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
spellingShingle |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent Rodriguez-Mori, Juan E. Microangiopatías trombóticas Tacrolimus Trasplante renal Thrombotic microangiopathies Tacrolimus Kidney transplantation |
title_short |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
title_full |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
title_fullStr |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
title_full_unstemmed |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
title_sort |
Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent |
dc.creator.none.fl_str_mv |
Rodriguez-Mori, Juan E. Mego-Arellan, Denese C. Sumire-Umeres, Julia Asato-Higa, Carmen Rodríguez-Mori, Juan E. Mego-Arellan, Denese C. Sumire-Umeres, Julia Asato-Higa, Carmen |
author |
Rodriguez-Mori, Juan E. |
author_facet |
Rodriguez-Mori, Juan E. Mego-Arellan, Denese C. Sumire-Umeres, Julia Asato-Higa, Carmen Rodríguez-Mori, Juan E. |
author_role |
author |
author2 |
Mego-Arellan, Denese C. Sumire-Umeres, Julia Asato-Higa, Carmen Rodríguez-Mori, Juan E. |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
Microangiopatías trombóticas Tacrolimus Trasplante renal Thrombotic microangiopathies Tacrolimus Kidney transplantation |
topic |
Microangiopatías trombóticas Tacrolimus Trasplante renal Thrombotic microangiopathies Tacrolimus Kidney transplantation |
description |
Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this condition presents in non-complete forms, which makes diagnosis difficult, and irreversible lesions may supervene. This case features the presence of a viral infection, and data suggesting rejection with the concomitant tacrolimus use. Therapy includes plasmapheresis and the use of monoclonal antibodies such as eculizumab. Nonetheless, in this particular case suspending therapy or switching from tacrolimus to another agent were good cost-effective measures. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-27 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/1056 10.35663/amp.2020.374.1056 |
url |
https://amp.cmp.org.pe/index.php/AMP/article/view/1056 |
identifier_str_mv |
10.35663/amp.2020.374.1056 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/1056/1243 |
dc.rights.none.fl_str_mv |
Copyright (c) 2020 ACTA MEDICA PERUANA info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 ACTA MEDICA PERUANA |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Colegio Médico del Perú |
publisher.none.fl_str_mv |
Colegio Médico del Perú |
dc.source.none.fl_str_mv |
ACTA MEDICA PERUANA; Vol. 37 No. 4 (2020): October - December ACTA MEDICA PERUANA; Vol. 37 Núm. 4 (2020): Octubre-Diciembre 1728-5917 1018-8800 reponame:Acta Médica Peruana instname:Colegio Médico del Perú instacron:CMP |
instname_str |
Colegio Médico del Perú |
instacron_str |
CMP |
institution |
CMP |
reponame_str |
Acta Médica Peruana |
collection |
Acta Médica Peruana |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1843978944342130688 |
score |
13.263243 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).